Cleocin Gel

By J. Eusebio. Sarah Lawrence College. 2018.

Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b order cleocin gel 20gm without prescription. Interferon beta in secondary progressive multiple sclerosis : daily clinical practice 20gm cleocin gel sale. Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study 942. Results of an on-going, open-label, safety- extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitdehaag BM, Polman CH. Quality of life during the first 6 months of interferon-beta treatment in patients with MS. A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. Interferon beta treatment in relapsing-remitting multiple sclerosis: a post-marketing study in Lombardia, Italy. Disease-modifying drugs for multiple sclerosis Page 93 of 120 Final Report Update 1 Drug Effectiveness Review Project 146. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. Minagar A, Murray TJ, Investigators PS, Minagara A, Murray TJ. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF. Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. Liver injury associated with the beta-interferons for MS: a comparison between the three products. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Disease-modifying drugs for multiple sclerosis Page 94 of 120 Final Report Update 1 Drug Effectiveness Review Project 162. Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Multiple sclerosis and depression: influence of interferon beta therapy. Borras C, Rio J, Porcel J, Barrios M, Tintore M, Montalban X. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b. Glatiramer acetate in treatment- naive and prior interferon-beta-1b-treated multiple sclerosis patients. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.

These cells can be grown with IL-2 and/or IL-15 for the initial few In contrast to the similarities mentioned above generic cleocin gel 20gm fast delivery, the marker CD56 is weeks cleocin gel 20 gm mastercard, but long-term culture requires feeder cell populations to specific to human NK cells and is not present on mouse NK cells. The CD56dim population consists of highly weeks, after which time cell death and measurable decreases in cytotoxic cells with low levels of cytokine production and is cytotoxic function and cytokine production occur. The CD56bright population, ences in initial cytotoxic capabilities can be attributed to the contrastingly, is poorly lytic, produces high levels of cytokines, and differences in perforin and granzyme B translation and protein is found primarily in the lymph nodes. In mice, perforin and granzyme B mRNA are the lymph nodes is another significant difference between human constitutively transcribed, but minimal levels of protein are and mouse NK cells, because human NK cells can be found detected until stimulation or activation of the NK cells that leads normally in the lymph nodes, whereas NK cells are not found there to rapid translation. Differences between human and mouse NK cells Mouse Human Defining NK cells CD3 CD122 (or NK1. NKp44 and NKp30 expressed Location In circulation and with immunostimulation or activation Found in circulation and in LNs at resting state without can be found in lymph nodes (LNs) immunostimulation Subsets 1. CD56dim (lytic in periphery) In vitro culture Can only be cultured for 2 weeks before dying or having Can be cultured and expanded for months with no impaired functionality significant changes to viability or functionality Resting lytic capability Weak: perforin and granzyme B stored as mRNA and Strong: perforin and granzyme B stored in granules as need to be translated proteins at high levels NKG2D ligands Rae-1, H-60, MULT1 MICA, MICB, ULBPs 228 American Society of Hematology Table 2. Issues concerning mouse models Common issues Description Ways to overcome Mouse strains 1. Differences in sensitivity to radiation (C57BL/6 more acknowledge and use these differences and are radioresistant than Balb/c) reflective of humans 3. Differences in viral resistance (C57BL/6 more resistant to murine cytomegalovirus than Balb/c mainly due to Ly49H expression) Husbandry Mice raised in specific-pathogen-free conditions that are Studies using mice not raised in such conditions not reflective of clinical conditions as comparison Genetics 1. Laboratory mice are all inbred from a common line, 1. Utilization of outbred mice as a comparison which is not reflective of the genetic diversity found in 2. Checking mice for any abnormal phenotypic humans and clinical studies signs and genetic testing if necessary 2. Genetic drift that occurs in a mouse line may go unnoticed and dramatically alter experiments Lifespan Mice live dramatically shorter lives than humans and Use mice of different ages, including older mice, studies that just use young mice may not reflect the which will be more reflective of human patients age and disease/immune status of typical human patients Disease susceptibilities 1. Differences in development of certain cancers Acknowledge differences and design experiments between mice and humans that can best replicate the human condition or 2. Species-specific pathogens that have altered provide an understanding of the mechanism of development of immune systems between humans disease or immune responses and mice Although the differences in human and murine NK cells may appear and show decreased production of IFN and reduced cytotoxic numerous and may seem to outweigh the usefulness of the mouse capabilities in vitro (Figure 2). Some ontogeny, function, and regulation, that were initially observed in studies supported the in vitro models with the licensed NK cells mouse studies have been validated with human NK studies. Mice allow for the modeling of complex disease states in were not due to potential inhibition by MHC-I recognition. The vast array of reagents, technologies, and genetic knowl- was one of the first studies showing in vivo functional differences edge developed for mice allow for the study of processes and between licensed and unlicensed NK cells, and it has significant dissection of mechanisms and therapies using NK cells that cannot clinical ramifications with the identification of the particular subset be performed using larger outbred animals because of the lack of of cells that mediate BMC rejection after HSCT. Therefore, the limitations different study looking at differences between the subsets in murine and issues concerning mouse models and the differences that exist CMV (MCMV) resistance showed that depletion of the unlicensed between human and mouse NK cells should be acknowledged and population resulted in significantly greater viral titers after infection noted, but by designing thoughtful and representative experiments compared with depletion of the licensed population. The researchers that can address the underlying mechanisms, functions, and prin- concluded that any benefit in functionality obtained by licensing ciples of NK cell biology, many of the differences can be accounted was outweighed by the inhibition that occurred because the licensed for and applied to humans (Table 2). The following sections will cells could actually recognize self and be inhibited. It is suggested that licensed cells are highly regulated to prevent now thought that NK cells go through a process analogous to overactivation and damage to self. Based on these studies, licensed positive selection of thymocytes in the thymus whereby NK cells NK cells appear to play a large role after HSCT (when NK cells are need to be able to detect and bind to self to become fully functional. In addition, receptors with different binding affinities to MHC-I haplotypes. Myeloid-derived suppressor cells have also cytokine producing capabilities. These cells are termed “educated” been shown to regulate and inhibit NK cell activity in patients with or “licensed. Shown is the process of NK cell licensing based on research by Kim et al. However, if it does not possess an inhibitory receptor capable of binding to self, it is unlicensed, hyporesponsive, and thus does not need inhibition. Clinical studies corroborated these findings on licensing in patients signaling pathway. These Delahaye et al found that NK cells that expressed 2 of the isoforms patients showed an increased and sustained expansion of licensed, of NKp30 had the expected outcome of mediating NK cell NKG2C NK cells that also produced increased levels of IFN , activation and lysis of the tumor targets, whereas the third isoform indicating that the licensed subset of NK cells may have a more resulted in NK cells producing immunosuppressive cytokines such significant role after HSCT, when patients are immunocompro- as IL-10. Studies have suggested that influenza hemagglu- licensing of NK cell subsets based on inhibitory receptor expression tinin is a ligand for NKp46. However, a recent clinical study demon- role of this receptor through NKp46-knockout mice and showed strated that unlicensed NK cells exhibited greater antibody- improved viral control through T-cell regulation in the knockout dependent cell-mediated cytotoxicity in neuroblastoma patients mice compared with wild-type. They concluded that, having the tools and reagents to try to determine other potential similar to the study by Orr et al on MCMV in mice,13 the licensed ligands and isoforms of the receptor, a better understanding of this cells were inhibited by the high expression of MHC-I that was receptor and the potential subsets of NK cells that express it can be maintained in the tumor targets. Therefore, our understanding of NK cell immunoregulatory capabilities the phenomenon of licensing and the disease states and immune An often-neglected aspect of NK biology and function is the role of conditions where it may be most significant is still limited.

The changing spectrum of the cutaneous manifestations of HIV disease effective 20 gm cleocin gel. Cowan FM cheap cleocin gel 20gm without a prescription, Humphrey JH, Ntozini R, Mutasa K, Morrow R, Iliff P. Maternal Herpes simplex virus type 2 infec- tion, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. Anal Dysplasia and Anal Cancer in HIV-positive Individuals: Prevention, Diagnosis, Treatment. Eosinophilic pustular folliculitis: a comprehensive review of treatment options. Esser S, Reimann G, Brockmeyer NH, HIV-assoziierte Tumoren. Fontes V, Machet L, Huttenberger B, Lorette G, Vaillant L. Recurrent aphthous stomatitis: treatment with colchicine. High rate of Bartonella henselae infection in HIV-positive outpatients in Johannesburg, South Africa. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. Disseminated Kaposi’s sarcoma syndrome in young homosexual men. Protease inhibitor-related paronychia, ingrown toenails, desquamative cheilitis and cutaneous xerosis. Garcia-Silva J, Almagro M, Pena-Penabad C, Fonseca E. Indinavir-induced retinoid-like effects: incidence, clinical features and management. Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome. High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy. Cutaneous reactions to alimentary tract medications: results of a seven-year surveillance program and review of the literature. Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED). Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. Gottlieb MS, Schroff R, Schanker HM, Fan PT, Saxon A, Weisman DO. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. Nail and mucocutaneous hyperpigmentation with azidothymidine therapy. Diffuse pigmentation (nail, mouth and skin) associated with HIV infection. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. Seborrheic dermatitis of the scalp: etiology and treatment. Dermatological immune restoration syndrome: does it exist? Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. Herpes zoster in HIV-1-infected patients in the era of highly active anti- retroviral therapy: a prospective observational study. Imaz A, Pujol M, Barragán P, Domínguez MA, Tiraboschi JM, Podzamczer D. Community associated methicillin- resistant Staphylococcus aureus in HIV-infected patients. James CW, McNelis KC, Cohen DM, Szabo S, Bincsik AK.

Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n buy 20gm cleocin gel free shipping, cro s s o v ers cleocin gel 20 gm on-line, Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? P N o valuesnot given for dem ographics num berof wom en at baseline in each group:MF 61/114,BDP 49/112,P L 46/104. McArthur Methodsnot N otreported Yes,however, Yes Described by N /A N /Asingle blind Yes 1994 specified theywere brief authorsas"single- N o U K and did not blind"however, N o m andate a m ethodsofm ask ing N o S P T. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria Graft N o/N R AuthorsreportIT T ,N otreported F air N R/N R/349 P regnantorbreastfeeding,receiving im m unotherapy 1996 however,excluded (unlessreceiving a stable dose foratleast2yearswith at U S A 2/349patientswho leastm oderate sym ptom sduring the lastragweed season); dropped out had asthm a requiring therapywith inhaled orsystem ic im m ediatelyafter corticosteroids;were dependenton nasal,oral,orocular random iz ation and decongestantsorantiiflam m atoryagents;orhad rhinitis data from 17 m edicam entosa;m ultiple drug allergies;a significant patientswere m edical condition and/orlong-term use ofm edication that invalidated leaving m ightinterfere with the study;clinicallyrelevantabnorm al 330ptsavailable laboratoryvalues,vital signs,orelectrocardiogram results; foranalysisof and use ofanyinvestigational drug within the previous30 efficacy days. F orprim ary efficacyauthors stated thatIT T pop showed sim ilar resultsbutdid not reportnum bers McArthur N o/N R AuthorsreportIT T ,N o F air N R/N R/88 T wosym ptom sforentryintothe studywere not 1994 however,for experienced in 1Mayto31August1993,had received oral U K com bined m ean corticosteroidsatanytim e during the 4week sbefore trial sym ptom score n= entry,had a bacterial,fungal,orviral airwayinfection,were 77Global efficacy orintended tobecom e pregnant,had received n=73,AEn=88 hyposensitiz ation therapyduring the previous12m onths, orhad severe asthm a. NCS Page 89 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Clas s Co ntro l Au tho r, naïv e gro u p Year, Ru n-in/ p atients s tandardo f Co u ntry Was ho u t o nly care Fu nding Relev ance Graft Run-in:N o N o Yes S upported bya 1996 W ash-out:yes grantfrom S chering- U S A P lough Research Institute. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria Langrick N o/N R N o N otreported F air N R/N R/69 P regnantorbreastfeeding,currentrespiratorytract 1984 infection ornasal abnorm alities,received system ic steroid England therapywithin the previous3m onthsoranti-allergy treatm entwithin the previousweek were noteligible. Ratner N o/N R N o Yes68ptsfrom F air 256/N R/218 U ncooperative orunable tocom plywith study 1996 one testing requirem ents,used nasal corticosteroidsornasal crom olyn U S A centerdue to sodium within 2week sofsystem ic corticosteroidswithin 4 low pollen count week sbefore random iz ation,had a total sym ptom severity and inabilityto score oflessthan 2orgreaterthan 7atrandom iz ation visit, show superior were asthm atic and required chronic bronchodilator efficacy therapy,orhad a historyorpresence ofclinicallysignificant m edical disorderthateitherwould have com prom ised the studyresultsorhave been detrim ental tothe patient W elsh N o N o N o F air N R/N R/120 N otspecificallylisted asexclusion criteria,however,pts 1987 were included iftheydid nothave nasal polyps,were not U S A pregnantorlactating,had good general health without illnessthatinterfere with the study NCS Page 92 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Greenbaum Methodsnot N otreported U nk nown: Yes DBbutm ethodsnot N /A DBbutm ethods Yes 1988 specified dem ographics specified notspecified Yes Canada notgiven but N o textindicates N o the groupsare "well balanced" NCS Page 94 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria S tern N o/N R Authorsreport N o F air N R/N R/635 H ad significantsym ptom sofsignsrelated tothe nose other 1997 doing an "all than those ofseasonal allergic rhinitis(perennial or U K,Denm ark patientstreated" atrophic rhinitis),anyobstructive structural abnorm alityin analysisand stated the nose,ornasal polyps. Acute orchronic infectious itwasnotdifferent sinusitisand iftheyhad experienced significantupper from the other respiratorytractinfection in the 2week spreceding the analysis. P tsusing topical nasal corticosteroid therapyduring resultswere not 1m onth before the studyorsystem ic corticosteroidsin the given asnum erical 2m onthspreceding the studywere excluded,aswere data only patientswhohad im m unotherapyforseasonal allergic description in the rhinitisin the 2yearspreceding the studyorastem iz ole text. Greenbaum N o/N R N o N o F air- N R/N R/122 <12yo,had k nown hypersensitivitytocorticosteroids, 1988 dem ographics including flunisolide;had active quiescenttuberculosisof Canada notgiven the respiratorytractoruntreated fungal,bacterial,or therefore results system ic viral infectionsorocularherpessim plex,orthose cannotbe with unhealed nasal ulcers,surgeryortraum a;had any reproduced. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Clas s Co ntro l Au tho r, naïv e gro u p Year, Ru n-in/ p atients s tandardo f Co u ntry Was ho u t o nly care Fu nding Relev ance S tern Run-in:N o N o Yes Grantfrom Astra 1997 W ash-out:N o DracoAB U K,Denm ark Greenbaum Run-in:N R N o Yes N otclearlyreported,Dem ographics 1988 W ash-out:N R however,requestfor notgiven Canada reprintstoAuthor from S yntex,Inc. NCS Page 96 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria H ebert N o/N R N o N o F air N R/N R/501 Asthm a requiring therapywith inhaled orsystem ic 1996 corticosteroids,crom oglycate,ornedocrom il;were k nown tobe unresponsive tonasal corticosteroids;were dependenton system ic corticosteroidsornasal decongestants;had an allergytocorticosteroids;orhad received potentcorticosteroid treatm entwithin the last m onth. Chronic m edication ora significantm edical condition which could interfere with the study;asthenia or grossobesity;clinicallyrelevantabnorm al laboratorytests, vital signs,orelectrocardiogram ;patientson im m unotherapy(unlesson a stable regim en foratleast6 m os. Certain concom itantm edicationswere restricted during the study,including corticosteroids(exceptforlow-potency topical preparationssuch as hydrocortisone),m astcell stabiliz ers, antihistam ines(apartfrom rescue loratadine),decongestants,aspirin, nonsteroidal anti-inflam m atorydrugs, and system ic antibiotics. NCS Page 98 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Clas s Co ntro l Au tho r, naïv e gro u p Year, Ru n-in/ p atients s tandardo f Co u ntry Was ho u t o nly care Fu nding Relev ance H ebert Run-in:N o N o Yes N otspecifically 8. NCS Page 99 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria Lum ry N o/N R N o N o F air N R/N R/152 Clinical evidence ofanysignificantphysical abnorm alities 2003 orabnorm al laboratoryvalues;nasal candidiasis,acute or U S A chronic sinusitis,significantnasal polyposisorothergross anatom ical deform ityofthe nose sufficienttoim pairnasal breathing;concurrentm edical conditionslik elytointerfer with the course ofthe study;use ofsystem ic corticosteroids in the previous42daysornasal orinhaled corticosteroids in the previous30days;use ofnasal crom olyn sodium in the previous28daysorastem iz ole in the previous60days; treatm entwith an investigational drug within 60days; com m encem entofim m unotherapywithin the previoussix m onths;use ofm edication forotherm edical conditionsthat m ightproduce orrelieve the signsand sym ptom sofallergic rhinitisforsixdayspriortoand throughoutthe treatm ent period;and pregnancy,lactation,orinadequate contraceptive precautionsin fem alesofchild-bearing potential NCS Page 101 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Clas s Co ntro l Au tho r, naïv e gro u p Year, Ru n-in/ p atients s tandardo f Co u ntry Was ho u t o nly care Fu nding Relev ance Lum ry Run-in:N o N o Yes Aventis 2003 W ash-out:Yesx P harm aceuticals, U S A 6days role notspecified NCS Page 102 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria S m all N o/N R N o,efficacyn=223 N o F air N R/N R/233 W om en whowere pregnantorofchildbearing potential and 1997 and safetyn=233 notpracticiing approved m ethod ofbirth control;P tm eeting Canada atleastone ofthe following criteria were excluded:a clinicallysignificant,renal,hepatic,cardiac,respiratory (including asthm a),neurologic,collagen-vascular,or psychiatric disorder;cancer;untreated fungal,bacterial,or viral infections;nasal septal ulcerorperforation;nasal surgeryortraum a;physical nasal obstruction greaterthan 50%;a historyofhabitual abuse ofnasal decongestants; use ofanysystem ic,nasal,inhaled corticosteroidswithin 30daysofscreening visit;use ofnasal sodium crom oglycate,anticholinergics,vasoconstrictors,or antihistam ines(exceptastem iz ole)within 7daysofthe screening visit;use ofastem iz ole within 60daysofthe screening visit;use oftopical,oral orboth typesof decongestantsm ore than three tim esperweek forthe previous3m onths(90days):cardiovasculardrugs, horm ones,neurolepticsoranyotherdrugsthatcan cause, suppress,orexacerbate the sym ptom sofallergic rhinits; im m unotherapyunless on a m aintenance regim en atthe tim e ofscreening; historyofhypersensitivityornonresponse to corticosteroids;and participation in another investigational studywithin 30daysofthe screening visit. S teroidswere notperm itted,exceptfororal contraceptivesand estrogen replacem enttherapy. NCS Page 104 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Clas s Co ntro l Au tho r, naïv e gro u p Year, Ru n-in/ p atients s tandardo f Co u ntry Was ho u t o nly care Fu nding Relev ance S m all Run-in:N o N o Yes Grantfrom Rhone- Race not 1997 W ash-out:yesx P oulene Rorer reported,M/F Canada 5-14days Canada,Inc. O ne equal authorfrom this age range 12-70 source aswell W ide varietyof allergensdue to m ulticenter, P ollen countnot reported. N otIT T ,single blind k eepsfrom being rated good NCS Page 105 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria LaF orce N o/N R N otclear,num bers N o F air-good N R/N R/238 Being treated with corticosteroidsorintranasal sodium 1994 notreported in crom olyn,required inhaled orsystem ic corticosteroid U S A resultsbutonly3 therapyforongoing asthm a,had an upperrespiratorytract outof238patients infection,oriftheywere scheduled toaltertheir withdrew from im m unotherapyregim en during the study,wom en atrisk of study pregnancy(postm enarchal orprem enopausal wom en and those notusing oral contraceptives)and patientswith any significantm edical disorderorim paired adrenal function as indicated byclinical laboratorytests.